BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 28264096)

  • 1. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.
    Gaiani A; Martinelli I; Bello L; Querin G; Puthenparampil M; Ruggero S; Toffanin E; Cagnin A; Briani C; Pegoraro E; Sorarù G
    JAMA Neurol; 2017 May; 74(5):525-532. PubMed ID: 28264096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of CSF NfL and tau in ALS.
    Schreiber S; Spotorno N; Schreiber F; Acosta-Cabronero J; Kaufmann J; Machts J; Debska-Vielhaber G; Garz C; Bittner D; Hensiek N; Dengler R; Petri S; Nestor PJ; Vielhaber S
    J Neurol; 2018 Nov; 265(11):2633-2645. PubMed ID: 30187162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.
    Illán-Gala I; Alcolea D; Montal V; Dols-Icardo O; Muñoz L; de Luna N; Turón-Sans J; Cortés-Vicente E; Sánchez-Saudinós MB; Subirana A; Sala I; Blesa R; Clarimón J; Fortea J; Rojas-García R; Lleó A
    Neurology; 2018 Oct; 91(17):e1619-e1628. PubMed ID: 30291183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.
    Abu-Rumeileh S; Vacchiano V; Zenesini C; Polischi B; de Pasqua S; Fileccia E; Mammana A; Di Stasi V; Capellari S; Salvi F; Liguori R; Parchi P;
    J Neurol; 2020 Jun; 267(6):1699-1708. PubMed ID: 32100123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.
    Poesen K; De Schaepdryver M; Stubendorff B; Gille B; Muckova P; Wendler S; Prell T; Ringer TM; Rhode H; Stevens O; Claeys KG; Couwelier G; D'Hondt A; Lamaire N; Tilkin P; Van Reijen D; Gourmaud S; Fedtke N; Heiling B; Rumpel M; Rödiger A; Gunkel A; Witte OW; Paquet C; Vandenberghe R; Grosskreutz J; Van Damme P
    Neurology; 2017 Jun; 88(24):2302-2309. PubMed ID: 28500227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.
    Lu CH; Macdonald-Wallis C; Gray E; Pearce N; Petzold A; Norgren N; Giovannoni G; Fratta P; Sidle K; Fish M; Orrell R; Howard R; Talbot K; Greensmith L; Kuhle J; Turner MR; Malaspina A
    Neurology; 2015 Jun; 84(22):2247-57. PubMed ID: 25934855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic value of CSF neurofilaments in a cohort of patients with motor neuron disease: A cross-sectional study.
    Gagliardi D; Faravelli I; Meneri M; Saccomanno D; Govoni A; Magri F; Ricci G; Siciliano G; Pietro Comi G; Corti S
    J Cell Mol Med; 2021 Apr; 25(8):3765-3771. PubMed ID: 33609080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis.
    Gille B; De Schaepdryver M; Goossens J; Dedeene L; De Vocht J; Oldoni E; Goris A; Van Den Bosch L; Depreitere B; Claeys KG; Tournoy J; Van Damme P; Poesen K
    Neuropathol Appl Neurobiol; 2019 Apr; 45(3):291-304. PubMed ID: 29908069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis.
    Falzone YM; Domi T; Mandelli A; Pozzi L; Schito P; Russo T; Barbieri A; Fazio R; Volontè MA; Magnani G; Del Carro U; Carrera P; Malaspina A; Agosta F; Quattrini A; Furlan R; Filippi M; Riva N
    Eur J Neurol; 2022 Jul; 29(7):1930-1939. PubMed ID: 35263489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.
    Halbgebauer S; Steinacker P; Verde F; Weishaupt J; Oeckl P; von Arnim C; Dorst J; Feneberg E; Mayer B; Rosenbohm A; Silani V; Ludolph AC; Otto M
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):68-74. PubMed ID: 34417339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilaments in Sporadic and Familial Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
    Shahim P; Norato G; Sinaii N; Zetterberg H; Blennow K; Chan L; Grunseich C
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival.
    Skillbäck T; Mattsson N; Blennow K; Zetterberg H
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Aug; 18(5-6):397-403. PubMed ID: 28631955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.
    Meeter LHH; Vijverberg EG; Del Campo M; Rozemuller AJM; Donker Kaat L; de Jong FJ; van der Flier WM; Teunissen CE; van Swieten JC; Pijnenburg YAL
    Neurology; 2018 Apr; 90(14):e1231-e1239. PubMed ID: 29514947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
    Verde F; Otto M; Silani V
    Front Neurosci; 2021; 15():679199. PubMed ID: 34234641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
    Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
    Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.
    Cousins KAQ; Shaw LM; Chen-Plotkin A; Wolk DA; Van Deerlin VM; Lee EB; McMillan CT; Grossman M; Irwin DJ
    JAMA Neurol; 2022 Nov; 79(11):1155-1164. PubMed ID: 36215050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis.
    Tortelli R; Copetti M; Ruggieri M; Cortese R; Capozzo R; Leo A; D'Errico E; Mastrapasqua M; Zoccolella S; Pellegrini F; Simone IL; Logroscino G
    Eur J Neurol; 2015 Jan; 22(1):215-8. PubMed ID: 24750431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies.
    Kmezic I; Samuelsson K; Finn A; Upate Z; Blennow K; Zetterberg H; Press R
    Eur J Neurol; 2022 Sep; 29(9):2810-2822. PubMed ID: 35638376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.